Insider Profile
Pimstone, Simon Neil
1
Companies Filed At
6
Open-Market Buys (2yr)
$130K
Buy Value (2yr, open-market)
Mar 27, 2026
Most Recent Trade
3
Credibility
Score
Score
40%
Hit Rate
-5.6%
Avg 90d Return
-6.3%
Median 90d Return
5
Evaluated Trades
+28.4%
Best Trade
-39.3%
Worst Trade
Hit rate and returns are based on 5 open-market buys with evaluable
90-day outcomes. Score reflects historical conviction, not a guarantee of future performance.
Limited signal — either below-average timing or insufficient trade history.
Cross-Company Track Record
14%
Hit Rate · 90d
-13.0%
Median Alpha · 90d
7
Closed Buys Evaluated
14%
Beat XIU
All-insider base rate:
59% hit rate
· +1.3% mean alpha
(n=11504)
cluster buyer
high frequency
size concentrated
Entry: closing price on SEDI filing date (point-in-time). Exit: 90 calendar days later.
Alpha vs XIU.TO (iShares TSX 60). Closed trades only. Not investment advice.
Research
7 closed buys with individual return outcomes available on the
Research plan.
| Date | Company | Dir. | Value |
|---|---|---|---|
| Mar 27, 2026 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $28K |
| Mar 27, 2026 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $24K |
| Mar 27, 2026 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $23K |
| Mar 27, 2026 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $19K |
| Mar 27, 2026 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $19K |
| Dec 15, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $86K |
| Dec 15, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $86K |
| Nov 14, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $200K |
| Sep 24, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $17K |
| Mar 31, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Sell | $350K |
| Mar 25, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $231K |
| May 13, 2024 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $178K |
| Jan 12, 2024 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $28K |
| Jan 12, 2024 |
$EPRX
Eupraxia Pharmaceuticals
|
Sell | $28K |
| Aug 18, 2023 |
$EPRX
Eupraxia Pharmaceuticals
|
Sell | $28K |
| Mar 09, 2021 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $440K |
Muted rows are plan purchases, compensation grants, or DRIP — not open-market.
Confluence Scores reflect the company's current score, not the score at time of trade.